Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minora Tomita, Mitsuhiko Kawaguchi, Harahiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with naïve chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56%) and was more frequent in older patient groups: 38%, 48%, and 77% for the

Original languageEnglish
Pages (from-to)54-63
Number of pages10
JournalHepatology
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
interferon alfa-2b
Therapeutics
Safety

ASJC Scopus subject areas

  • Hepatology

Cite this

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. / Iwasaki, Yoshiaki; Ikeda, Hiroshi; Araki, Yasuyuki; Osawa, Toshiya; Kita, Keiji; Ando, Masaharu; Shimoe, Toshinari; Takaguchi, Kouichi; Hashimoto, Noriaki; Kobatake, Toshitsugu; Tomita, Minora; Kawaguchi, Mitsuhiko; Kobashi, Harahiko; Sakaguchi, Kohsaku; Shiratori, Yasushi.

In: Hepatology, Vol. 43, No. 1, 01.2006, p. 54-63.

Research output: Contribution to journalArticle

Iwasaki, Y, Ikeda, H, Araki, Y, Osawa, T, Kita, K, Ando, M, Shimoe, T, Takaguchi, K, Hashimoto, N, Kobatake, T, Tomita, M, Kawaguchi, M, Kobashi, H, Sakaguchi, K & Shiratori, Y 2006, 'Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C', Hepatology, vol. 43, no. 1, pp. 54-63. https://doi.org/10.1002/hep.20984
Iwasaki, Yoshiaki ; Ikeda, Hiroshi ; Araki, Yasuyuki ; Osawa, Toshiya ; Kita, Keiji ; Ando, Masaharu ; Shimoe, Toshinari ; Takaguchi, Kouichi ; Hashimoto, Noriaki ; Kobatake, Toshitsugu ; Tomita, Minora ; Kawaguchi, Mitsuhiko ; Kobashi, Harahiko ; Sakaguchi, Kohsaku ; Shiratori, Yasushi. / Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. In: Hepatology. 2006 ; Vol. 43, No. 1. pp. 54-63.
@article{8fa8c721a6924b758da0b8c37e4a7085,
title = "Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C",
abstract = "In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with na{\"i}ve chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56{\%}) and was more frequent in older patient groups: 38{\%}, 48{\%}, and 77{\%} for the",
author = "Yoshiaki Iwasaki and Hiroshi Ikeda and Yasuyuki Araki and Toshiya Osawa and Keiji Kita and Masaharu Ando and Toshinari Shimoe and Kouichi Takaguchi and Noriaki Hashimoto and Toshitsugu Kobatake and Minora Tomita and Mitsuhiko Kawaguchi and Harahiko Kobashi and Kohsaku Sakaguchi and Yasushi Shiratori",
year = "2006",
month = "1",
doi = "10.1002/hep.20984",
language = "English",
volume = "43",
pages = "54--63",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

AU - Iwasaki, Yoshiaki

AU - Ikeda, Hiroshi

AU - Araki, Yasuyuki

AU - Osawa, Toshiya

AU - Kita, Keiji

AU - Ando, Masaharu

AU - Shimoe, Toshinari

AU - Takaguchi, Kouichi

AU - Hashimoto, Noriaki

AU - Kobatake, Toshitsugu

AU - Tomita, Minora

AU - Kawaguchi, Mitsuhiko

AU - Kobashi, Harahiko

AU - Sakaguchi, Kohsaku

AU - Shiratori, Yasushi

PY - 2006/1

Y1 - 2006/1

N2 - In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with naïve chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56%) and was more frequent in older patient groups: 38%, 48%, and 77% for the

AB - In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with naïve chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56%) and was more frequent in older patient groups: 38%, 48%, and 77% for the

UR - http://www.scopus.com/inward/record.url?scp=33644804915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644804915&partnerID=8YFLogxK

U2 - 10.1002/hep.20984

DO - 10.1002/hep.20984

M3 - Article

VL - 43

SP - 54

EP - 63

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -